Archives
-
Protease Inhibitor Cocktail EDTA-Free: Assay Logic
2026-09-22
Learn how a Protease Inhibitor Cocktail EDTA-Free protects transient protein complexes and phosphorylation-sensitive samples. This guide connects protease control to LAG-3/TCR signaling assays, offering practical decisions beyond standard extraction advice.
-
Lipidated Nanophotosensitizer Blocks Tumor Metastasis
2026-09-22
The reference study developed a palmitic acid-displayed nanophotosensitizer that traces tumor extracellular vesicles (TEVs) and generates reactive oxygen species inside both tumor cells and TEVs. In female mouse models, near-infrared treatment suppressed primary tumors while disabling TEV-mediated communication, offering a preclinical strategy for addressing tumor growth and metastasis together.
-
Multiplex PBMC Flow Cytometry for Immunomodulator Screening
2026-09-21
Brox and Hackstein developed and validated a multiplex flow cytometry assay that measures T-cell proliferation and activation alongside B-cell costimulatory responses in human PBMCs. The study shows how defined stimulation conditions, primary-cell biology, and Z-factor validation can improve the resolution and reproducibility of immunomodulator screening.
-
Bone Transport and TGF-β1 in Diabetic Foot Ulcer Repair
2026-09-21
A 2026 rat study links bone transport with TGF-β1/TGFBR1 activation, angiogenesis, immune regulation, and improved diabetic foot-ulcer healing. Its combined proteomic, molecular, histological, and pathway-inhibition design provides a mechanistic framework for testing how osteo-immune signals influence chronic wound repair.
-
Phosphotungstic Acid Negative Stain Solution Guide
2026-09-20
Turn fragile particles, glycoprotein complexes, bacteria, and organelles into high-contrast electron microscopy targets with a ready-to-use 2% negative stain. This workflow pairs practical morphology control with glycan-focused coronavirus research while clearly separating structural imaging from antiviral efficacy testing.
-
BIBP 3226 Trifluoroacetate in NPY Research
2026-09-19
BIBP 3226 trifluoroacetate enables receptor-level dissection of NPY Y1 and NPFF signaling in cardiac, neuronal, and cellular assays. This workflow-focused guide shows how to connect adipose-neural signaling with cAMP, calcium-handling, and arrhythmia readouts while managing selectivity, solubility, and vehicle controls.
-
CHIR 99021 trihydrochloride Organoid Workflow
2026-09-18
CHIR 99021 trihydrochloride gives researchers a tunable GSK-3 inhibitor for linking stem-cell self-renewal, organoid differentiation, and metabolic assays. This practical guide translates pathway control into dose-ranging workflows, assay choices, and troubleshooting strategies for organoid and type 2 diabetes research.
-
circRHOBTB3 in Metastatic Prostate Cancer
2026-09-18
Song and colleagues identify circRHOBTB3 as a downregulated tumor suppressor in prostate cancer and define a mechanism linking circular RNA localization to NONO-dependent MAOA transcription. The study also shows that SRSF9 regulates circRHOBTB3 biogenesis, providing a mechanistic framework for interpreting circRNA loss during metastatic progression.
-
Cabozantinib: A Time-Resolved RCC Signaling Guide
2026-09-17
Cabozantinib (XL184) produces distinct acute and chronic signaling states in renal cell carcinoma models. This guide explains how phosphoproteomic timing, MET site interpretation, and motility assays can prevent misclassification of adaptive remodeling as treatment failure.
-
Calpain Inhibitor I, ALLN: Lab Guide
2026-09-17
Calpain Inhibitor I, ALLN (SKU A2602) is a water-insoluble cysteine-protease inhibitor used to investigate calpain- and cathepsin-associated proteolysis in apoptosis assays, inflammation research, and ischemia-reperfusion injury models. This guide focuses on stock preparation, controls, and interpretation; the reagent is for research use only and is not a diagnostic or therapeutic product.
-
DiscoveryProbe Protease Inhibitor Library: HTS Guide
2026-09-16
The 825-compound DiscoveryProbe Protease Inhibitor Library supports a practical progression from biochemical protease inhibition to cell-based mechanism mapping. Its pre-dissolved, automation-ready format helps researchers compare protease activity modulation, apoptosis phenotypes, and disease-relevant responses while reducing compound-handling variability.
-
From USP42 Biology to Precision Biotin Detection
2026-09-16
Translational oncology requires more than a compelling mechanism: it requires readouts that connect pathway perturbation with reproducible cellular and tissue evidence. This article examines how Streptavidin – Cy5 can support the validation of USP42–JNK/p38 biology while defining practical controls, competitive tradeoffs, and the boundaries between preclinical research and clinical translation.
-
DiscoveryProbe Protease Inhibitor Library Workflow
2026-09-15
Build reproducible biochemical, apoptosis, cancer, and infectious-disease screens around 825 pre-dissolved protease inhibitors. The workflow combines automation-ready compound handling with orthogonal validation so screening hits become interpretable mechanistic leads rather than isolated assay signals.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-09-15
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 or LLY507 in kidney injury models, the authors connect SMYD2 inhibition with reduced epithelial–mesenchymal transition, extracellular matrix remodeling, inflammatory cytokines, and Smad3/STAT3 signaling, while highlighting important limits for translation beyond the experimental setting.
-
DiscoveryProbe Immunology/Inflammation Library
2026-09-14
The DiscoveryProbe Immunology/Inflammation Compound Library is a curated 295-compound collection for immunomodulator screening, inflammation target validation, and immune pathway profiling. L1042 combines diverse small molecules with pre-dissolved 10 mM DMSO formatting and a workflow-compatible set of inflammatory and immune-related targets.